Revvity’s in-vitro diagnostic products unit EUROIMMUN has partnered with ALPCO-GeneProof, a Czech Republic-based molecular diagnostics company, to expand the distribution of GeneProof PCR kits across the European Union (EU).

The collaboration leverages the distribution network and support infrastructure of EUROIMMUN alongside the molecular diagnostic technologies of ALPCO-GeneProof.

Under the agreement, EUROIMMUN will provide a range of 42 molecular diagnostic assays from ALPCO-GeneProof. These assays utilise the “one workflow” technology, streamlining usage and ensuring compatibility with various qPCR instruments.

Moreover, EUROIMMUN will introduce the croBEE nucleic acid extraction system, thereby enriching the diagnostic offerings.

The complete lineup of GeneProof PCR kits encompasses assays designed for transplant and immunocompromised patients, sexually transmitted infections (STIs), bloodborne pathogens, respiratory infections, thrombotic mutations, neuroinfections, and antibiotic resistance.

EUROIMMUN CEO Dirk Beecker said: “Entering into the partnership with ALPCO-GeneProof, EUROIMMUN is relying on an established and experienced provider for molecular diagnostic assays.

“It will allow EUROIMMUN’s customers to benefit from a vastly expanded high-quality assay portfolio that can be run on established real-time PCR cyclers.”

Based in Germany, EUROIMMUN specialises in developing, manufacturing, and distributing test systems to aid in disease diagnosis, along with providing software and automation solutions for test execution and analysis.

Laboratories across more than 140 countries are said to rely on EUROIMMUN products for diagnosing autoimmune and infectious diseases, allergies, and conducting genetic analyses.

ALPCO-GeneProof CEO Erik Allen said: “Having EUROIMMUN as a partner brings a strong focus to the European Union for the GeneProof products. Combining our high-quality IVDR cleared kits with their expertise in the diagnostic space and strong commercial presence means more customers can access the fast-growing GeneProof infectious disease assays.”